Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Getinge AB, Audiocast with teleconference, Q3'24

By Inderes10/18/2024, 8:00 AM
Getinge

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Mattias Perjos
00:02 - 09:00

Thank you very much and thank you everyone for joining today. We can move directly to page number two and discuss the key takeaways from the quarter, please. So we look back at a quarter where we continued to see strong global market momentum for our products. Order intake growth for Getinge as a whole increased by ten percentage points, of which organic growth amounted to 7.4%. And this is thanks to positive development in all business areas except for Life Science. And it's a good geographic spread as well. When it comes to the order intake. Net sales increased by 3.5% in the quarter, whereas organic growth was flat compared to last year. Adjusted gross margin in Life Science and Surgical Workflows improved in the quarter. However, it decreased in Acute Care Therapies and also for the group as a consequence of this, mainly due to negative mix inflation and under-absorption. This was partly mitigated then by healthy price increases, which signals that our products are attractive to customers. This was partly mitigated by healthy price increases, which signal that our products are attractive to customers. And even if our financial leverage has increased somewhat after the acquisition of Paragonix Technologies Inc., our financial position remains solid. With that, we can move over to page number three, please. So, I wanted to take this opportunity to highlight some of the key activities and events in the quarter. And if we start with sustainability and quality in the quarter. The notified body TÜV SÜD reinstated the CE certificate for the HLS and PLS consumables that are used for ECLS or ECMO therapy. TFC also extended the temporary suspension of the CE certificate for the CardioSave Intra-Aortic Balloon Pump until July 1st, 2025. This decision has no material financial impact for us, and the extended time period will now allow us to improve the product in line with the regulatory requests that we have. We're still able to supply the key markets with our intra-aortic balloon catheters. And furthermore, as informed earlier in the quarter, we made a provision of 482 million SEK related to the ongoing negotiations with the Brazilian Comptroller General of the Union (CGU). If we then move to offerings and customers, our Servo ventilators received official cybersecurity clearance, which is called Authority to Operate certification from the US Defense Health Agency. This means that the ventilators are allowed to be purchased by the US Department of Defense and operate within their strict networking environments. We consider this an important quality stamp and proof of our strategy to provide safe device connectivity for our customers within our Life Science business. We acquired assets of the US-based company Intact Solution LLC, with technology that makes aseptic treatment and transfer safer and more effective throughout the complete bio-processing value stream. In September, we also completed the acquisition of Paragonix Technologies Inc. , which is a leading U.S. company within the fast-growing market for organ transport products and services. We see a strong fit with Getinge's existing product portfolio, our technologies and also our global sales reach. Paragon will form a new product area within Acute Care Therapies called Transplant Care, and will be an additional lever for us in our purpose as a company to help save more lives globally. We can then move over to page four, please. So as I mentioned earlier, order intake grew by 10% in the quarter, of which 7.4% was organic growth. Net sales increased by 3.5%, and 0.2% of this was organic growth. Order intake grew in all regions, and the increase in organic order intake was especially strong in America, driven by Acute Care Therapies and Surgical Workflows. From a net sales perspective, we had organic growth around 1.2% in Americas and EMEA, whereas APAC declined organically compared to last year's strong performance. We can then move over to page number five, please. This takes us to the outlook then, where we reiterate our previous guidance for 2024. And we expect organic net sales growth to be in the range of 2 to 5%. In addition to this, we expect recent acquisitions to contribute between 3 to 5%. Can we move to page number six, please? So we move into dissecting the order intake per business area a bit in Acute Care Therapies. The organic order intake increased strongly during the quarter, mainly in critical care, cardiac surgery, and cardiopulmonary for life sciences. The order intake declined organically, mainly due to fewer orders for steam sterilizers compared to the comparable quarter last year. There was a positive performance in Bio-Processing, and growth in sterile transfer also continued in Surgical Workflows. Then, the organic order intake increased overall, mainly thanks to a double-digit increase both in infection control and in digital health solutions, while orders in surgical workplaces declined slightly. So all this together summarizes to 7.4% organic order intake growth, and in actuals, growth was 10%. Let's move over to page number seven then. So looking at the sales breakdown for the quarter, organic net sales in Acute Care Therapies decreased slightly during the quarter, mainly due to a lower number of consumables sold in cardiac assist and lower sales of ILS hardware in cardiopulmonary. Furthermore, temporary supply chain challenges have impacted net sales negatively in the quarter, but we are expecting this situation to improve in Q4 and in Acute Care Therapies, we saw continued growth within critical care as well. And if we move to life science, the life science organic net sales declined mainly due to lower sales in Bio-Processing and sales of isolators. This was partially offset by the strong performance in sterile transfer. However, net sales from High Purity New England in the quarter made up for all and a little bit more of this. If we can move to Surgical Workflows. Organic net sales for Surgical Workflows increased following growth in all product categories, and also, I want to point out that the acquisition of Healthsmart continues to contribute materially to growth. Surgical Workflows acquisitions contributed to an increase in net sales of 535 million SEK in the quarter. Currency had a 286 million negative impact on net sales for the Getinge group in the quarter. Recurring revenue increased while sales of capital goods were down year on year. Can I move over to page number eight, please? So looking then at the gross margin and the gross profit. The adjusted gross profit decreased by 91 million to 3,799 million in the quarter, where currency effect impacted negatively by 151 million SEK. The group's adjusted gross margin declined by 2.8 percentage points versus last year, mainly attributable to negative mix, inflation, and under-absorption. This was partly offset by healthy price increases. Inflation is mainly attributable now to employee costs. We have seen a decline when it comes to material cost. We see good traction in normalizing the cost of materials thanks to the purchasing initiatives that we have been working hard on for the last couple of years. Also, for Acute Care Therapies, the adjusted gross margin decreased by 5.6 percentage points, mainly due to lower sales, negative mix effect due to under-absorption, and higher quality improvement costs compared to the comparable quarter. For Life Science, the adjusted gross margin increased by 2.9 percentage points as a result of price adjustments, productivity improvements, and also mix, and this was partly offset by higher materials and employee costs. Surgical Workflows adjusted gross margin increased by 1.2 percentage points to a large extent, thanks to the strong performance of acquired health, marked by price adjustments, and also mix effects. Overall, I'd say we are pleased to see that the integration of the acquisitions made last year has developed according to plan, even a little bit better in some cases, and that the business performance has been above expectations. So on that positive note, I hand over to Agneta and page number nine.

Agneta Palmér
09:01 - 12:12

Thank you, Matthias. Adjusted EBITDA declined by 198 million and the margin came in three percentage points lower, mainly due to the decline in the gross margin. Adjusted gross profit had a negative effect on the margin by 2.7 percentage points, due to what was just mentioned by Matthias. However, on the OpEx side, adjusted for currency, we really start to see encouraging signs on OpEx, which had a 0.4 positive impact on the margin in the quarter due to operating leverage and positive contributions from acquisitions. Adjusted for currency, depreciation, and amortization had no impact on the margin. Finally, effects negatively impacted the margin by 0.7 percentage points. All in all, this resulted in an adjusted EBITDA of $903 million and a margin of 11.5%. Over to page ten, please. Free cash flow amounted to around 0.4 billion, and lower operating profit and higher financing costs contributed negatively. Working capital, however, increased to a lesser extent than last year. We do see positive developments in operating receivables, where we have been able to leverage learnings from previous periods and apply those in many of our markets. The provision made for Brazil has no impact on the cash flow in the quarter. Working capital days continue to be well below 100. We are now at 91 days. We continue to be below trend on operating return on invested capital, with 10.4% on a rolling 12-month basis, which is still above the cost of capital. Let's then move to page 11, please. The change in net debt year over year is due to the acquisitions that were finalized in the fourth quarter of 2023 and in this quarter, taking us to 11.3 billion in net debt at the end of the third quarter. If we adjust for pension liabilities, we are at 8.6 billion. And this brings us to a leverage of two times EBITDA, which is well below the two and a half times we have previously communicated as a threshold. If we adjust for pension liabilities, leverage is at 1.5 times EBITDA. This signals that we remain in a solid financial position even after the recent strategic acquisitions. And this is according to our plan. And this is according to our plan. We intend to work this down going forward. Cash amounted to approximately 2.2 billion by the end of the quarter. So all in all, we can conclude that the financial position continues to be strong. Let's then move to page 13 and back to you, Mattias.

Mattias Perjos
12:12 - 13:29

All right. Thank you, Agneta. And on page 13, I just wanted to take the opportunity to summarize the key takeaways. Again, the main one is that we continue to see strong order intake growth across regions. Most of our product categories have been affected, as well as by a temporary supply challenge. Challenges have impacted both net sales and especially margins in Acute Care Therapies in the quarter, but we are expecting the situation to improve in the fourth quarter, even if financial leverage has increased somewhat after the acquisition of Paragonix Technologies Inc., our financial position remains solid and we reiterate our guidance for the full year. So, 2 to 5% organic net sales growth. In addition to this, we expect the recent acquisitions to contribute 3 to 5 percentage points to growth. So the current priorities for us are addressing the remaining challenges in Acute Care Therapies. This is the number one priority for the whole company. We're also working on sustainable productivity improvements and remain cost-conscious when it comes to expanding our business. And we continue creating added value for our customers, both through organic development, the investments that we make in R&D, for example, and also inorganically, like with the acquisition of Paragon. With that said, I open up for questions. Thank you.

Operator
13:32 - 13:35

The next question comes from Eric Castle at Danske Bank. Please go ahead.

Unknown 1
13:37 - 14:03

Hi. Good morning everyone. So, first question. I mean, in the report you mentioned that consumer demand for balloon pumps and hardware is down in ECMO? Naturally, some might think that the latter could have some impact. But I also know that communications were really challenging for both last year. I mean, I just have to ask, is there an aspect here of market share losses in either of these business areas, or is it just purely communications?

Mattias Perjos
14:05 - 14:25

Yeah. Thank you, Eric. It's a bit difficult to say. I think it's definitely a communications effect in there. We have no information on any significant market share losses. I think we're expecting that customers will find a second source for ECMO. Hardware, hardware? But there's nothing material in the quarter that we can call out due to this.

Unknown 1
14:28 - 14:47

All right. Thank you. Um, and then how much of the strong order intake that you're seeing now within Act relates to, you know, ECMO consumables. And are you seeing any sort of trends, based on these issues that you have now in Q3, that customers are looking to maybe build their own safety stocks in Q4?

Mattias Perjos
14:48 - 15:18

Yeah, I don't think we have been able to supply enough for anyone to really build safety stocks. I think we have gotten out of the back-order situation outside of the EU markets, at least. But we have no evidence of anyone trying to stockpile this. And we are now, from the first week of October, back to delivering with the new packaging solution also to the CEE market. We're hoping for a more stable supply situation going forward.

Unknown 1
15:20 - 15:27

Um, I was thinking more about the order side. It sounded like you were talking about deliveries. Um, but it's the same story for orders.

Mattias Perjos
15:27 - 15:37

Yes, true. Sorry, I misunderstood that. Uh, then. Now I think there's nothing I can call out in the order pattern that indicates any stocking at customers.

Unknown 1
15:39 - 15:54

Okay, perfect. Just the last question. I mean, how high were the costs related to, you know, quality and regulatory this quarter when it comes to the Cardiosave Intra-Aortic Balloon Pump? And have you changed your view in any way for where the full-year cost will end up?

Mattias Perjos
15:55 - 16:18

No, it's broadly in line with what we've communicated. We don't detail out everything that we invest in upgrading products and fixing changes like the changeover we had in the factory with the HLS Plus production. So nothing really to add of material nature in that regard.

Unknown 1
16:20 - 16:23

All right. Thank you. I'll jump back and see you.

Unknown 2
16:23 - 16:24

Thank you.

Operator
16:27 - 16:32

The next question comes from Matthias Waddesdon from SEB. Please go ahead.

Unknown 3
16:34 - 17:09

Yes. Hi. Good morning. I will start off by slightly tweaking the question on ECMO, which was strong in Q2 in cardiopulmonary but weaker in Q3, with what appeared to be stability in production in Q2 and problems arising in September. So, based on the coming quarters for ECMO, do you see growth mainly being reliant on your internal supply stability, if you get what I mean. And then, if you could comment on what makes you comfortable that production will be more stable going forward. That's the first one.

Mattias Perjos
17:11 - 17:46

Yeah, I think we have certainly historically found that our production capacity has been a limiting factor when it comes to growing the business. I think with the new packaging now implemented for key markets and the production being up and running again, we're certainly hoping for a more stable supply and that we won't be the bottleneck to growth. That's as much as I can say on that going forward here. I think it's anyone's guess right now what the flu season will do this year. I mean, the last couple of years we've seen really no effect from that. But that's something we'll have to evaluate in the coming months here.

Unknown 2
17:49 - 17:49

Okay.

Unknown 3
17:50 - 18:17

Thank you for that. And the next one would be orders. If we look at life science, orders remain well above sales. In the last 12 months. So, the question is, I guess, do you see organic sales growth starting here in Q4 already? And also, I appreciate you won't comment on the sort of margins in the order book, but what kind of product areas do you expect to be growing strongly here into 2025? That's the next one.

Agneta Palmér
18:19 - 18:49

We anticipate that Q4 will be a strong delivery quarter for Life Science. Um, if we look at the margins going forward, as you can see in the last couple of quarters, we have had a pickup of the beta sterile transfer, which is a comparatively high margin product within life science. Um, but it is, as you know, very subject to the product mix in life science.

Unknown 2
18:52 - 18:52

Good.

Unknown 3
18:52 - 19:08

And I will limit myself to one more question. So you also flagged critical care having strong orders, which I assume advances the largest part. So if you could comment on to what extent this is due to an easing of competitive pressure in this area? That's the last one.

Agneta Palmér
19:09 - 19:26

I will say we confirm that, of course, we have an uptick in orders, but it's too soon to confirm that it is due to the movements in the market. So we'll have to revisit that, as I anticipate it will be the first half of 2025 before we can conclusively determine the results.

Unknown 3
19:28 - 19:29

Thank you very much.

Mattias Perjos
19:30 - 19:31

Thank you.

Operator
19:35 - 19:41

The next question comes from Christopher Liljeberg from Carnegie Investment Bank. Please go ahead.

Unknown 2
19:43 - 19:43

Thank you.

Unknown 3
19:43 - 19:54

I have three questions. First, could you quantify the effect on sales from the production or delivery issues you have for ECMO consumables in the quarter?

Agneta Palmér
19:57 - 20:05

So, to quantify the effect of reinstating the CE mark, is that your question, or can you clarify, please?

Unknown 3
20:07 - 20:08

Yes, exactly.

Agneta Palmér
20:09 - 20:22

Yes. So, we will share this. It is not material overall, but there is an effect of some between 50 plus million, shift between the third and the fourth quarter.

Unknown 3
20:25 - 20:26

On sales.

Agneta Palmér
20:26 - 20:27

On sales.

Unknown 3
20:28 - 20:37

Okay. And you also said there were some additional costs for this. So is it possible to say how much this has impacted earnings in the quarter?

Unknown 1
20:38 - 20:38

We will not.

Agneta Palmér
20:39 - 20:53

I will not isolate and quantify that effect. But there is certainly an effect, as we've had to make adaptations to production and supplier interactions. .

Unknown 2
20:55 - 20:55

Okay.

Unknown 3
20:55 - 21:07

But if we instead look at the total impact on the data from all the quality issues, which has varied between 100 and 200 million, it was not possible to give that figure for the quarter.

Agneta Palmér
21:08 - 21:38

Yes, exactly. So if we say we do have, as you mentioned, those elevated quality costs in line with those levels in Q3. The main pieces, as we have already mentioned, include the under absorption piece, which is partly due to necessary adaptations to our production processes, and the increased scrapping. But the main thing is the negative mix and the currency that we have mentioned.

Unknown 3
21:41 - 21:46

We can't specify whether it's 100, 200 million, or even more this quarter.

Agneta Palmér
21:47 - 22:01

We've reiterated what we've said for the full year: those are the levels of quality-related costs. And then additionally, we have had some under absorption for this in the third quarter and some scrapping. I would say.

Unknown 3
22:03 - 22:08

Okay. And could you remind me what you had said the impact will be for the full year?

Agneta Palmér
22:09 - 22:18

We initially projected costs to be in the range of half a billion, but with the added under absorption issues, we are now trending slightly above that estimate.

Unknown 3
22:19 - 22:58

Okay. Uh, my other two questions. Could you comment on the strong order growth in Surgical Workflows that we observed a couple of years ago as a catch-up from the pandemic? And now it seems to be picking up again, particularly in the US. Where are you gaining better market momentum? And then my third question relates to the comment about acquiring business that contributed to organic growth from Q4. Is it possible to say how much those businesses are growing right now? Thank you.

Mattias Perjos
23:02 - 24:04

Yes, I can comment on infection control. As I said, we've had a good comeback after the pandemic, as you stated. Right now, in the quarter, the main positive contributions were from infection control and digital health. I wouldn't say that's a continued pandemic. Uh, catch up. I mean, in some cases there are large products in infection control that we win, which have a positive impact. Digital health is a smaller part of Surgical Workflows, but it exhibits good underlying growth momentum. And there's been a long period where customers have been very focused on post-pandemic operational struggles that they've had. There's been a lot of large IT investments that have somewhat displaced the types of solutions we provide in digital health. So it's encouraging, I think, to see that there seems to be bandwidth and budget for these types of investments. Uh, now, as well. So those are the main factors. I would not say that we are gaining market share in the US or anything like that. We're trying to hold the fort there, but there's no market share gain.

Agneta Palmér
24:06 - 24:27

And then when it comes to the acquisitions, we adhere to the guidance that we have provided for the full year. And as we mentioned, we have a contribution of $535 million in Q3 and we have healthy growth in these areas. So that is what we expect to see in line for Q4 as well.

Unknown 2
24:29 - 24:30

Okay.

Unknown 3
24:30 - 24:30

Thank you.

Mattias Perjos
24:31 - 24:32

Thank you.

Operator
24:35 - 24:40

The next question comes from David Johansen from Nordic Markets. Please go ahead.

Unknown 2
24:42 - 24:42

Hi.

Unknown 4
24:42 - 24:59

Thank you for taking my questions. The first question I had was about the additional $97 million restructuring you have done in Acute Care Therapies. You know, is this quality cost for the new packaging solution for ECMO consumables, or is this something else new this quarter? Thank you.

Agneta Palmér
25:00 - 25:16

Yeah. So that is a number of rightsizing initiatives that we are running across different functions of our company to address our cost base. So it's not primarily linked to the quality piece.

Unknown 4
25:18 - 25:34

Okay. Then I'd like to follow up on that. I was wondering about the large layoff you conducted at your main production facility in the US. Can you elaborate on what has happened there and what the reason is for reducing headcount to this degree? Thank you.

Agneta Palmér
25:36 - 25:58

We will not comment on that individual case, but it's not a large layoff that we have done at the main facility. Layoff that had occurred at our main facility. We always review our teams and how they should deliver in the best way. We have the best prerequisites to deliver. We have done that in Wayne, but it's not the main thing.

Unknown 4
25:58 - 26:05

Okay. Okay. But it's one of the initiatives taken in the 97 million restructuring.

Agneta Palmér
26:05 - 26:07

Yes, that is correct. Yeah.

Unknown 4
26:08 - 26:19

Okay. Perfect. Then just a quick one on the regulatory situation for Cardiac Assist. Europe has something new come up, you know. Or what is the reason for the extended suspension period? Thank you.

Mattias Perjos
26:21 - 26:47

Yeah. No, nothing new has come up. It's just that there, like we indicated when we received the CE certificates to suspend it, some of the technical challenges with the existing balloon pump platform just can't be solved in a short period of time. So I think the extension now allows us to work through the remaining couple of challenges that we have yet to resolve. So. But nothing new has happened. It's in line with expectations.

Unknown 4
26:49 - 26:51

Okay, perfect. Those are my questions.

Mattias Perjos
26:51 - 26:52

All right. Thank you.

Operator
26:56 - 27:01

The next question comes from Eisner, from Morgan Stanley. Please go ahead.

Unknown 5
27:03 - 27:19

Hi. Good morning. Thanks for taking my questions. My first question is about the asset restructuring costs. Kind of similar to the question before this. What functions are you reducing and which segments within Act does this relate to? And does this reflect a lower growth outlook for Act in 2025?

Agneta Palmér
27:20 - 27:48

Yes. So it is broadly. So I will not single out any specific functions, but it's both within the supply chain of the business area, in the sales organization, and in the supporting functions that we work with rightsizing initiatives. We do not expect this to have any negative effect, if anything, a positive effect on our profitability going forward.

Mattias Perjos
27:50 - 28:13

I think it's important to state overall that it's really about trimming and adjusting to inflation across all our businesses. So we have restructuring costs not only for Act, but also for our other parts of the business as well. This is a normal course of business and really just trying to mitigate the reality of inflation that we've had for the last couple of years.

Unknown 5
28:15 - 28:38

Okay. One question on the topic, I believe you mentioned a 50 million push out due to ECMO supply issues. That doesn't really explain the magnitude of the drop in sales in Q3. Can you just explain what was the driver of the shortfall in your Act business in Q3?

Agneta Palmér
28:40 - 28:58

Yes, I would say firstly, we had very tough comps from last year. So that's important to keep in mind that we had some catch-up of deliveries coming into Q3 of last year. So, that, I would say, is the main impact apart from the commission.

Unknown 5
29:00 - 29:08

Okay. My last question is on the life science business. What was the growth rate for China specifically, and did the trend worsen sequentially into October?

Mattias Perjos
29:09 - 29:24

We don't disclose growth rates on individual country levels, but we called out double-digit growth in both China and the US for Bio-Processing in the quarter. But those are the only details we will share.

Unknown 5
29:26 - 29:27

Okay. Thank you very much.

Unknown 2
29:27 - 29:28

Thank you.

Operator
29:31 - 29:36

The next question comes from Oliver Reinberg from Kepler Cheuvreux. Please go ahead.

Unknown 3
29:39 - 29:39

Yes. Thanks very much.

Mattias Perjos
29:39 - 29:40

For taking.

Unknown 3
29:40 - 29:40

My questions.

Unknown 6
29:41 - 30:01

And three questions also from my side. Mattias, can you provide some insights on the aftermath? I mean, the FDA letter occurred in May, so we are now half a year down the road. Can you provide some insight into what you hear from the FDA, from clients, and from competitors? I think you mentioned that there. There's a broader trend to find alternative sources. Any kind of update on the situation would be helpful. Thank you.

Mattias Perjos
30:02 - 31:26

Hey. Yeah, sure. I mean, there isn't that much of an update to provide. There's been no new news from the FDA. We continue to have the weekly meetings that we've had for a long time with them. And we do see eye to eye on what we need to implement on our product platforms to address the concerns that they have raised in the letter to healthcare providers. So that work is progressing according to plan. So nothing new on that front when it comes to customers. We've spent a lot of time with our local organization clarifying what this actually means. There's been a lot of confusion and misunderstandings about the content of the letter. So there's been a dialogue with many customers around this. The main concerns raised by customers still relate to the supply situation. Being able to get products primarily for ECMO therapy. We do expect, though, that customers will develop alternative sources and have a plan B in place. We don't see any major cancellations or anything today, but I think like we said, when this first happened in May, we do expect customers to think about their sourcing strategy and have an alternative to us as well. And we don't see any major impact from this right now, but we still keep an eye on it month by month and quarter by quarter.

Unknown 6
31:28 - 31:45

Okay. Perfect. Thank you. And the second question regarding China, can you provide a broader update on the demand situation there, any observations on stimulus trends, or if you have any insights into when the stimulus packages might support your demand situation.

Mattias Perjos
31:45 - 32:05

Yeah, we're aware of the stimulus package, and we continue to monitor it and keep a dialogue with customers. We do expect that there will be some tailwind from this. We can't see that it has impacted the quarter at all so far. So if anything, it's a future effect of this. And something we'll have to come back with more information on when we see any material changes.

Unknown 6
32:07 - 32:38

Okay. So, the third and last question is on the economic transaction. It was obviously a larger capital deployment at ten times EV sales. Can you just provide a bit more insight on the growth prospects, like what growth do you expect in heart and lung? How significant is the contribution from abdomen and any kind of data? What do you expect outside the US? Any insights on the overall sales perspective and when you expect this to achieve the desired cost of capital would be helpful in framing the discussion.

Mattias Perjos
32:38 - 33:28

Yes, we will come back. We've owned them for two weeks in the third quarter, so it's a little bit too early to draw too many conclusions. What I can say, though, is that we're extremely happy to have now Paragonix Technologies Inc. as part of our portfolio. It’s a great strategic fit, especially with our cardiopulmonary business in action. The reception from customers has been exceptionally positive. Everyone that we've interacted with, and Patagonix Technologies Inc. closed the quarter with very good momentum. Uh, and we expect that to continue. The growth drivers for this market, we expect to be sustainable for the foreseeable future, up to the next ten years. But I really can't, with this short period that we've owned the company, make too many other conclusions. So we look forward to coming back to this once we've closed out 2024.

Unknown 6
33:30 - 33:32

All right. Understood. Thanks very much.

Mattias Perjos
33:32 - 33:33

Thank you.

Operator
33:37 - 33:42

The next question comes from David Adlington from J.P. Morgan. Morgan. Please go ahead.

Unknown 7
33:44 - 34:12

Hey, guys. Thank you for the questions. I really just wanted to focus on margins. Obviously, you've reiterated the revenue guidance, but we're now in the middle of October. Still no margin guidance. I just wondered if you could give us maybe some expectations for this year and thoughts into next year, just relative to the fact that you're down 300 basis points year-on-year this quarter and 30 basis points year to date. Just wondering if you're expecting any margin expansion this year with a stronger Q4. And then just also, that trajectory into next year would be helpful as well. Thank you.

Agneta Palmér
34:13 - 34:33

Yeah. Thanks, David. We will stick by what we communicated back in May in the capital markets, which is a rather flattish margin for this year. In absolute numbers. That is, of course, an increase given the growth that we have. But we stick by that perspective.

Unknown 7
34:39 - 34:41

And then thoughts on next year given the moving parts.

Agneta Palmér
34:43 - 34:49

You will have the same answer there. We stick by that outlook that we gave in May.

Unknown 7
34:52 - 34:53

Okay. Thanks.

Mattias Perjos
35:08 - 35:10

All right. Thanks, David. David. Any other questions here?

Operator
35:13 - 35:18

The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.

Unknown 8
35:19 - 35:38

Yes. Good morning. Firstly, as a follow-up on David's question. Could you remind me what you guided for in May in terms of margin outlook for 2025? That would be my first question, please.

Agneta Palmér
35:38 - 35:45

Yes, we have shared that material, but it's a rather flattish development.

Unknown 8
35:46 - 35:48

Also for 2025.

Agneta Palmér
35:49 - 35:50

Yes.

Unknown 8
35:52 - 36:37

Yep. Excellent. Thank you. So. And then on ECMO and HLS, it sounded like you said you haven't lost any market share, but you expect customers to start using other suppliers. And we have seen recently also new products being approved here in Europe, from one of the competitors. Um, for example, um, on ECMO. So my question is what type of growth outlook do you see for your ECMO and intra-aortic balloon pump franchise for the coming year.

Unknown 2
36:39 - 36:39

With.

Unknown 8
36:39 - 36:55

With regard to, you know, I mean, I understand you don’t typically provide guidance on specific products, but some kind of direction would be helpful in relation to your overall organic growth guidance?

Unknown 2
36:55 - 36:56

Yeah, yeah.

Mattias Perjos
36:56 - 37:51

No, absolutely. In this particular matter, we have already provided some guidance earlier. When it comes to our cardiopulmonary business, which essentially includes ECMO and ECLS therapy, we expect an approximate growth of around 8% for this business over time. Bear in mind, though, that it is a somewhat lumpy business, partly due to the supply chain and quality challenges that we've had. But the underlying growth for the therapy is expected to be around 8%. Balloon pumps are a different story. That’s always been, or at least in recent history, a slower growth category. So, underlying growth there is more in the range of 2 to 3%. Uh, and obviously, there is still some lumpiness, as you've seen in the last couple of years, when it comes to both supply but also some of the regulatory hurdles that we need to pass for this business.

Unknown 8
37:53 - 38:06

Okay. Thank you for that level of detail. And you still expect to be able to grow cardiopulmonary by 8% even with increased competition.

Mattias Perjos
38:07 - 38:43

I think the beauty of this is that it's a growing therapy overall, with a lot of potential for therapy and indication expansions that can be done. And I think if you look at, for example, the stent business where we were alone for quite some time and had new entrants expanding the market, we do expect to be able to grow around 8%. Even with the new competition. We do expect this. This segment will grow as a whole. It's a very powerful therapy for patients and offers room for indication expansion. So in short, the answer is yes.

Unknown 8
38:43 - 39:00

Great. Thank you. My last question is for clarification. You talked about delayed shipments here in September of roughly 50 million. Is it fair to assume that that had a negative impact then on EBITA of 30 million?

Agneta Palmér
39:02 - 39:03

That is correct.

Unknown 8
39:03 - 39:11

Which we then should add back to Q4 if, well, provided that the shipments take place now in October.

Unknown 9
39:11 - 39:12

Yes.

Agneta Palmér
39:12 - 39:29

And so that's a fair assumption on the sort of margin of those products. Then we have had other additional costs in Q3 to adjust production to this new CE Mark product.

Mattias Perjos
39:30 - 39:50

I think it's important to keep in mind that it's a complex operation, the manufacturing of these products. It's not only the products that don't get shipped and the margin impact; we're also producing these now in new packaging. Under partly new conditions, which have led to additional costs during the quarter as well. And under-absorbed.

Unknown 8
39:50 - 40:14

But in terms of adjustments, I tried to modify my figures ahead of the report. And so, I took out a little bit more. So now, when I need to put that back into Q4, the costs are obviously already sort of gone. But is the 30 million in EBITA a good approximation of this shipment? Yes.

Unknown 9
40:14 - 40:17

That's a good proxy for the value of those. Excellent.

Unknown 8
40:17 - 40:19

Yes. Excellent. Thank you.

Unknown 2
40:20 - 40:21

All right. Thank you.

Unknown 8
40:21 - 40:21

That's all for me.

Unknown 2
40:22 - 40:23

Thank you. Thank you.

Operator
40:24 - 40:29

The next question comes from Rikard Kranz from Handelsbanken. Please go ahead.

Unknown 10
40:32 - 41:04

Hi. And thank you for taking my questions. First one on the guidance. So, you know, I guess some of us out here are curious and wondering why that was. The organic growth guidance wasn't narrowed given where we are in the year. You know, it's quite a wide range of outcomes it implies for Q4. So maybe you could elaborate on some of the swing factors that could lead you to the low versus the high end, respectively. And where do you expect to end the year, on the higher or the lower end of the growth guidance? I'll start there. Thank you.

Unknown 2
41:05 - 41:05

Yes.

Agneta Palmér
41:05 - 41:35

Thank you for that question. So we will stick by what we have communicated in terms of guidance. I will not provide a narrowing span. I will say this: you've seen the order book. It's very strong. We have all the teams lined up to deliver this in Q4, but there are risks on the timing. So just to say that this is why we still remain with the plan for a high-supply, high-production Q4 ahead of us.

Unknown 10
41:38 - 42:22

Okay, that's clear. Thank you. And secondly, following up a bit on the US Cardiosave Intra-Aortic Balloon Pump franchise. So you mentioned that you see signals of customers possibly diversifying, but it would be interesting to hear a bit more about the visibility into customer behavior. Would a customer inform you if they intended to transition away or switch? Do you think that the recent HLS supply disruptions could increase the risk of customers transitioning, given that you also mentioned that supply is a critical concern for many customers?

Mattias Perjos
42:23 - 43:29

Yeah, I didn't say that. We've seen a lot of customers starting to transition. I've said that we would be surprised if they didn't create Plan B's and create a second source for this. And we know that there are discussions going on with customers here, but you have the whole range of customers, some saying that no, they will stick with the platform they're happy with from Getinge. Others said that yes, most likely we will need to find a second source at least as well. So, the impact of that is much too early to say. So I think that's really all the light we can shed on it when it comes to the supply situation. The supply constraints in Q3 were more for the CE market. So not for the US. I think the US supply situation has improved over the last few months. Uh, the main frustration earlier with customers was that they hadn't had enough supply. I think we are out of a back order situation now in the US, so that should not be a factor that creates mitigation to competitive platforms.

Unknown 10
43:32 - 43:41

Very clear. And just a final question on the FDA quality record backlog. How are you tracking towards resolving the backlog?

Mattias Perjos
43:42 - 43:54

There's been really good progress in the third quarter. We are well over 99% done with that now and expect in the fourth quarter to resolve the remaining open issues.

Unknown 10
43:57 - 43:59

Very helpful. Thank you for taking my questions.

Unknown 2
43:59 - 44:00

Thank you.

Operator
44:03 - 44:15

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. The next question comes from Eisner from Morgan Stanley. Please go ahead.

Unknown 5
44:17 - 44:39

Hi. Just thanks for fitting me in. Just a housekeeping question for Agneta. On the below EBIT items, should we expect any more one-off impacts in Q4 or 2025 from either the Brazilian provisions or the act restructuring? And then on the interest costs, these were running a bit higher in Q3 compared to the first half's run rate. So, would it be fair to assume a more elevated figure for Q4? Thank you.

Agneta Palmér
44:39 - 45:23

Yes. Thank you for those questions. For Brazil, it is, as we have communicated, not final yet, but this is the best assessment. And we don't expect any material changes in Q4 for restructuring. We are, as mentioned, running a number of rightsizing and productivity initiatives. And some of those will impact, though not to the same extent as in Q3, but there will be some impact also in Q4. And then finally, coming to the interest expense that is related to the higher debt level and increased net debt as a consequence of the acquisition of Paragonix Technologies Inc. And this is completely according to plan.

Unknown 5
45:28 - 45:28

Thank you.

Agneta Palmér
45:29 - 45:30

Thank you.

Operator
45:30 - 45:36

The next question comes from Christopher Liljeberg from Carnegie Investment Bank. Please go ahead.

Unknown 3
45:38 - 46:02

Yeah. Hi. I want to follow up on your comment about margin before I understand the comment about flattish margin this year. But for next year, could you maybe explain the rationale for what will not make the margin improve next year? If you would have a lower impact from quality costs, would there be less cost inflation? Demand seems to be quite strong.

Unknown 2
46:03 - 46:03

Thank you.

Agneta Palmér
46:04 - 46:57

Um, so in the guidance that we have given, that is what we stick by, so to speak. And, as you know, we are very subject to mix. We have a slightly different mix coming into 2025. So that, with high growth in some of the acquisition areas mainly then in Surgical Workflows, which has very good profitability for us, impacts the margins overall from a mixed perspective for the company. So that is part of it. And also, we see stronger growth in some of the product areas with slightly different margin composition. But we do expect, like you say, that we will remain on elevated quality cost levels also. Last year, we did not provide guidance on the exact levels here, but that is part of it as well.

Unknown 3
47:01 - 47:02

Okay.

Unknown 2
47:02 - 47:03

Thank you.

Operator
47:07 - 47:13

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Mattias Perjos
47:15 - 47:26

Great. Thank you very much. I think we've already gone through the summary here, so nothing else to add from our side other than thanking you for taking the time to join us today and wishing you a good rest of the day. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…